1219694-61-7

Basic information

• Product Name: ethyl pyrazolo[1,5-a]pyrazine-3-carboxylate
• Synonyms: ethyl pyrazolo[1,5-a]pyrazine-3-carboxylate;Pyrazolo[1,5-a]pyrazine-3-carboxylic acid, ethyl ester
• CAS NO: 1219694-61-7
• Molecular Formula: C9H9N3O2
• Molecular Weight: 191.19
• Mol File: 1219694-61-7.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: ethyl pyrazolo[1,5-a]pyrazine-3-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl pyrazolo[1,5-a]pyrazine-3-carboxylate(1219694-61-7)
• EPA Substance Registry System: ethyl pyrazolo[1,5-a]pyrazine-3-carboxylate(1219694-61-7)

Safety Data

• Hazardous Substances Data: 1219694-61-7(Hazardous Substances Data)

Usage

Uses

Ethyl Pyrazolo[1,5-a]pyrazine-3-carboxylate acts as a useful reagent in the regiocontrolled synthesis of pyrazolo[1,5-a]pyrazines.

Upstream product

• 290-37-9 1,4-pyrazine 
• 623-47-2 propynoic acid ethyl ester 
• 68-12-2 N,N-dimethyl-formamide 
• 37622-90-5 4-ethoxycarbonylpyrazole 
• 57489-85-7 1-aminopyrazin-1-ium 2,4,6-trimethylbenzenesulfonate 
• 53975-16-9 1-aminopyrazin-1-ium iodide 

Downstream Products

• 1331768-75-2 pyrazolo[1,5-a]pyrazine-3-carbonitrile 
• 53902-93-5 3-bromopyrazolo[1,5-a]pyrazine 
• 53902-76-4 pyrazolo[1,5-a]pyrazine-3-carboxylic acid 

Relevant articles and documents

HETEROCYCLIC COMPOUND AND USE THEREOF

The present invention provides a heterocyclic compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and expected to be useful as an agent for the prophylaxis or treatment of major depression, bipolar disorder, migraine, p

Heteroaryl imidazolone derivatives as jak inhibitors

New heteroaryl imidazolone derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).

PYRAZOLE DERIVATIVES AS JAK INHIBITORS

New pyrazole derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).